Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
An mRNA flu vaccine delivers a lab-made strand of messenger RNA, packaged in a tiny lipid bubble, that instructs your cells to produce a harmless copy of an influenza surface protein so your immune system learns to recognize and fight the real virus. The mRNA never enters your cell's nucleus, does not alter your DNA, and degrades within days, while the protective antibodies it triggers can last through flu season. Because mRNA can be reprogrammed quickly without growing virus in eggs, these vaccines may match circulating strains more closely and can potentially be combined with COVID-19 shots, though several candidates remain in late-stage trials. There are important details about effectiveness, side effects, timing, and who benefits most, so see below to understand more.
If you are already feeling feverish, achy, congested, or run down and are unsure whether it is flu, a cold, or something else, guessing wastes time when early treatment matters most; take a free, instant, online symptom check to better understand what your symptoms may mean and what step to take next.
Last reviewed for medical accuracy: 09/24/2026
What Is an mRNA Flu Vaccine, and How Does It Work?
Seasonal influenza (“flu”) causes hundreds of thousands of hospitalizations and tens of thousands of deaths each year in the U.S. Traditional flu shots use inactivated (killed) virus or viral proteins to train your immune system. An mRNA flu vaccine represents a newer approach—one that proved its worth during the COVID-19 pandemic and is now being adapted to fight influenza.
In this article, you’ll learn:
An mRNA flu vaccine delivers a small snippet of genetic code (messenger RNA, or mRNA) that instructs your cells to produce one of the flu virus’s surface proteins—usually hemagglutinin (HA). Unlike inactivated or protein-based shots, this technology does not contain live virus and cannot cause influenza.
Key points:
The process involves several steps:
Lipid nanoparticle delivery
• The mRNA is encased in a tiny fatty capsule (lipid nanoparticle) to protect it and help it enter your cells.
Cellular uptake and protein production
• After injection (usually in your upper arm), the nanoparticle fuses with cells at the injection site.
• The cell’s machinery reads the mRNA and builds the flu protein (antigen).
Immune system activation
• Cells display the antigen on their surfaces.
• Nearby immune cells (dendritic cells) pick up the antigen and travel to lymph nodes.
• B cells and T cells learn to recognize the antigen and multiply.
Immune memory formation
• Some B cells become long-lived “memory” cells that produce antibodies if you meet the flu virus again.
• Memory T cells help kill infected cells and coordinate a rapid, effective response.
Advantages of mRNA Flu Vaccines
Compared with traditional flu shots, mRNA technology offers several potential benefits:
• Faster development
– Once the genetic sequence of a new flu strain is known, mRNA vaccines can be designed in days.
– Manufacturing can begin without growing the virus in eggs or cell culture first.
• Better strain matching
– Because the process is faster, it’s easier to update the shot if a new strain emerges late in flu season.
• Strong immune response
– mRNA vaccines tend to generate both antibody and T-cell responses, which may offer broader protection.
• No risk of infection
– There’s no live virus in the vaccine, so it can’t cause the flu.
mRNA flu vaccines are promising, but there are considerations:
• Storage requirements
– Some mRNA formulations require ultracold or frozen storage. Newer versions may be stable at standard refrigerator temperatures, but guidelines vary.
• Side effects
– Similar to other vaccines, you may experience soreness, fatigue, headache, or low-grade fever for a day or two.
– Serious adverse events are rare but under continuous monitoring.
• Annual dosing
– Like all flu vaccines, mRNA shots are given each fall to match circulating strains.
Extensive clinical trials and real-world data (especially from mRNA COVID-19 vaccines) have shown that mRNA technology is generally safe:
Common, mild side effects (usually 1–2 days)
Rare but serious side effects (under careful review)
If you experience intense chest pain, difficulty breathing, high fever lasting more than 48 hours, or other alarming symptoms, seek medical care immediately.
Current recommendations (subject to updates) mirror those for traditional flu shots:
• Everyone 6 months and older, especially those at higher risk:
– Pregnant people
– Adults 65 and older
– People with chronic health conditions (asthma, diabetes, heart disease)
– Residents of long-term care facilities
• Healthcare workers and caregivers, to protect themselves and vulnerable individuals
Your healthcare provider can help you decide which flu vaccine formulation is best for you.
Before your appointment:
After your shot:
Even with vaccination, you can still catch the flu. If you develop fever, cough, body aches or other flu-like symptoms, early treatment can reduce complications. You might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help identify when you need professional care.
Scientists are working on:
These advances could make flu prevention more effective and convenient.
Vaccination is a key step in protecting yourself from influenza, but it’s not a substitute for medical advice. If you experience any life-threatening or serious symptoms—such as difficulty breathing, severe chest pain, sudden confusion, or a high fever that won’t come down—seek emergency care immediately. For other concerns about vaccination or flu symptoms, always speak to your doctor.
An mRNA flu vaccine uses a snippet of genetic code to teach your immune system to recognize and attack the influenza virus. It offers faster development, potentially stronger and broader protection, and no risk of live-virus infection. Most people tolerate it well, with only mild, short-lived side effects. As the technology evolves, mRNA flu vaccines may become your go-to annual shot.
Remember: getting vaccinated, monitoring symptoms early—and talking to a healthcare professional about any serious concerns—are the best ways to stay healthy this flu season.
(References)
* Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2021 Apr;28(3-4):117-129. doi: 10.1038/s41434-020-00204-y. Epub 2020 Oct 22. PMID: 33093657; PMCID: PMC7580817.
* Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine. 2021 Apr 15;39(16):2190-2200. doi: 10.1016/j.vaccine.2021.03.038. Epub 2021 Mar 24. PMID: 33771389; PMCID: PMC7987532.
* Le T, Sun C, Chang J, Zhang G, Yin X. mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases. Viruses. 2022 Feb 15;14(2). doi: 10.3390/v14020401. Epub 2022 Feb 15. PMID: 35215994; PMCID: PMC8877136.
* Montero DA, Vidal RM, Velasco J, Carreño LJ, Torres JP, Benachi O MA, Tovar-Rosero YY, Oñate AA, O'Ryan M. Two centuries of vaccination: historical and conceptual approach and future perspectives. Front Public Health. 2023;11:1326154. doi: 10.3389/fpubh.2023.1326154. Epub 2024 Jan 9. PMID: 38264254; PMCID: PMC10803505.
* Russell CA, Fouchier RAM, Ghaswalla P, Park Y, Vicic N, Ananworanich J, Nachbagauer R, Rudin D. Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines. Hum Vaccin Immunother. 2024 Dec 31;20(1):2336357. doi: 10.1080/21645515.2024.2336357. Epub 2024 Apr 15. PMID: 38619079; PMCID: PMC11020595.
* Cowling BJ, Okoli GN. Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine. Drugs. 2024 Sep;84(9):1013-1023. doi: 10.1007/s40265-024-02083-8. Epub 2024 Aug 21. PMID: 39167316; PMCID: PMC11438668.
* Terstappen J, Hak SF, Bhan A, Bogaert D, Bont LJ, Buchholz UJ, Clark AD, Cohen C, Dagan R, Feikin DR, Graham BS, Gupta A, Haldar P, Jalang'o R, Karron RA, Kragten L, Li Y, Löwensteyn YN, Munywoki PK, Njogu R, Osterhaus A, Pollard AJ, Nazario LR, Sande C, Satav AR, Srikantiah P, Stein RT, Thacker N, Thomas R, Bayona MT, Mazur NI. The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access. Lancet Infect Dis. 2024 Dec;24(12):e747-e761. doi: 10.1016/S1473-3099(24)00455-9. Epub 2024 Sep 23. PMID: 39326422; PMCID: PMC12311909.
* Casmil IC, Jin J, Won EJ, Huang C, Liao S, Cha-Molstad H, Blakney AK. The advent of clinical self-amplifying RNA vaccines. Mol Ther. 2025 Jun 4;33(6):2565-2582. doi: 10.1016/j.ymthe.2025.03.060. Epub 2025 Apr 3. PMID: 40186353; PMCID: PMC12172325.
* Aunins EA, Phan AT, Alameh MG, Dwivedi G, Cruz-Morales E, Christian DA, Tam Y, Bunkofske ME, Peñafiel AZ, O'Dea KM, Merolle M, Furey C, Scott P, Vonderheide RH, Hensley SE, Kedl RM, Weissman D, Hunter CA. An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses. Sci Immunol. 2025 Jun 6;10(108):eads1328. doi: 10.1126/sciimmunol.ads1328. Epub 2025 Jun 6. PMID: 40478935; PMCID: PMC13012528.
* Scott J, Abers MS, Marwah HK, McCann NC, Meyerowitz EA, Richterman A, Fleming DF, Holmes EJ, Moat LE, Redepenning SG, Smith EA, Stoddart CJ, Sundaram ME, Ulrich AK, Alba C, Anderson CJ, Arpey MK, Borre E, Ladines-Lim J, Mehr AJ, Rich K, Watts C, Basta NE, Jarolimova J, Walensky RP, Dugdale CM. Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026. N Engl J Med. 2025 Dec 4;393(22):2221-2242. doi: 10.1056/NEJMsa2514268. Epub 2025 Oct 29. PMID: 41160817.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.